文献速递淋巴瘤造血干细胞移植与细胞治疗

原发性玻璃体视网膜淋巴瘤:诊断与管理的挑战

Primary vitreoretinal lymphoma: a diagnostic and management challenge.
PubMed 文献 · Blood · 2021-01-01

原发性玻璃体视网膜淋巴瘤(PVRL)是仅累及眼内、无脑部受累的原发性中枢神经系统淋巴瘤(PCNSL)罕见亚型,可致永久性视力丧失和中枢神经系统复发(主要死因)。诊断需眼科与细胞学家协作,联合白细胞介素水平、分子生物学和影像学辅助;治疗上玻璃体内注射甲氨蝶呤或利妥昔单抗或局部放疗可清除眼内肿瘤细胞但不预防中枢复发,基于大剂量甲氨蝶呤的系统治疗可能降低风险。

要点

  • PVRL诊断困难,需眼科与细胞学紧密协作,联合IL水平、分子及影像辅助。
  • 局部治疗可清除眼内肿瘤细胞,但不能预防CNS复发。
  • 系统大剂量甲氨蝶呤化疗±局部治疗或可降低CNS复发风险。

核心结论

  • PVRL虽临床过程看似惰性,但可致永久性视力丧失和CNS复发,后者是主要死因,诊断和治疗仍具挑战。

研究设计与样本

  • 本文为综述,未报告系统检索范围或样本量。

主要发现

  • PVRL发病机制不明,肿瘤细胞可能起源于CNS外,迁移至眼内并在免疫许可微环境中增殖。
  • PVRL显示偏倚的免疫球蛋白库,提示存在抗原选择。
  • 玻璃体内注射甲氨蝶呤或利妥昔单抗或局部放疗可有效清除眼内肿瘤细胞,但不能预防CNS复发。
  • 基于大剂量甲氨蝶呤化疗的系统治疗,联合或不联合局部治疗,可能降低CNS复发风险。
  • 复发时可考虑强化巩固化疗后行干细胞移植;单药伊布替尼、来那度胺和替莫唑胺对复发PVRL有效,应作为一线治疗进行测试。

关键数值与推荐

  • 诊断需联合临床眼科检查、白细胞介素水平、分子生物学和影像学;因玻璃体中淋巴瘤细胞罕见且脆弱,并非总能识别。
  • 基于临床检查的疗效评估可通过测量细胞因子水平改善,但仍需细化。

临床怎么用

  • 疑似PVRL应多学科协作,综合细胞学、IL水平、分子及影像学尽早诊断。
  • 局部治疗可清除眼内病灶,但需关注CNS复发风险,可考虑系统大剂量甲氨蝶呤化疗。
  • 复发患者可考虑强化化疗后干细胞移植,或单药伊布替尼、来那度胺、替莫唑胺。

局限性

  • PVRL罕见且玻璃体中淋巴瘤细胞脆弱,细胞学识别不总是可行。
  • 治疗结论多来自异质性回顾性或小队列研究,需多机构前瞻性研究验证。
  • 疗效评估基于临床检查联合细胞因子水平,仍需进一步细化。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Primary vitreoretinal lymphoma (PVRL) is a rare form of primary central nervous system (CNS) lymphoma (PCNSL) arising in the intraocular compartment without brain involvement. Despite its apparent indolent clinical course, PVRL can cause permanent vision loss and CNS relapse, the major cause of death in patients with PVRL. The pathophysiology of PVRL is unknown. As in PCNSL, the transformation of the tumor cells likely originates outside the CNS, before the cells migrate to the eye and proliferate within an immune-permissive microenvironment. PVRL exhibits a biased immunoglobulin repertoire, suggesting underlying antigen selection. The diagnosis remains challenging, requiring close coordination between ophthalmologists and cytologists. Because of their rarity and fragility in the vitreous, lymphoma cells cannot always be identified. Interleukin levels, molecular biology, and imaging are used in combination with clinical ophthalmological examination to support the diagnosis of PVRL. Multi-institutional prospective studies are urgently needed to validate the equivocal conclusions regarding treatments drawn from heterogeneous retrospective or small cohort studies. Intravitreal injection of methotrexate or rituximab or local radiotherapy is effective at clearing tumor cells within the eyes but does not prevent CNS relapse. Systemic treatment based on high-dose methotrexate chemotherapy, with or without local treatment, might reduce this risk. At relapse, intensive consolidation chemotherapy followed by stem cell transplantation can be considered. Single-agent ibrutinib, lenalidomide, and temozolomide treatments are effective in patients with relapsed PVRL and should be tested as first-line treatments. Therapeutic response assessment based on clinical examination is improved by measuring cytokine levels but still needs to be refined.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Soussain C, Malaise D, Cassoux N, et al. Primary vitreoretinal lymphoma: a diagnostic and management challenge. Blood. 2021. PMID: 34036310. doi:10.1182/blood.2020008235

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。